Uwe Bicker - Sanofi Insider

SNYNF -- USA Stock  

USD 80.15  0.000002  0.00%

Independent Director

Mr. Uwe Bicker was Independent Director of Sanofi SA since May 14 2008. He is also Member of the Strategy Committee of the Company. Additionally he serves as Member of the Supervisory Board of Foundation Aventis and of Future Capital AG as well as Member of the Consulting Committee of Morgan Stanley. As of 2011 he was the Dean at the Medical Faculty of the Heidelberg University where he was Professor since 1983 and he also became Managing Director at the University Clinic of Mannheim in 2011. He is also an Honorary Senator of Heidelberg University and an Honorary Doctor of the Klausenburg University. During his professional career Mr. Bicker was also appointed as Trustee of Fondation Aventis. Between 1975 and 1994 he held various positions at Boehringer Mannheim GmbH and from 1994 to 2004 he held various positions at Hoechst group. Until 2012 Mr. Bicker also served as Chairman of the Supervisory Board of Siemens Healthcare Diagnostics Holding GmbH Vice Chairman of the Supervisory Board of Epigenomics AG and of Definiens AG. He is a Physician and holds a Doctorate in Chemistry and Medicine.
Age: 69  Director Since 2008  Ph.D    
33 1 53 77 40 00  http://www.sanofi.com

Management Efficiency

The company has return on total asset (ROA) of 4.5 % which means that it generated profit of $4.5 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.75 % meaning that it generated $6.75 on every $100 dollars invested by stockholders.
The company has accumulated 19.18 B in total debt with debt to equity ratio (D/E) of 26.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sanofi has Current Ratio of 1.68 which is within standard range for the sector.

Similar Executives

Entity Summary

It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi is traded on OTC Market in USA.Sanofi (SNYNF) is traded on OTC Market in USA. It is located in 54, Rue La Bo?tie and employs 106,566 people.

Sanofi Leadership Team

Dominique Carouge, President
Claudie Haignere, Director
Olivier Brandicourt, CEO
Pascale Witz, President, MBA
Serge Weinberg, Chairman
Suresh Kumar, President
Kathleen Tregoning, President
Sebastien Martel, President, MBA
William Sibold, President, MBA
Peter Guenter, President
Fabienne Lecorvaisier, Director
George Grofik, President
Karen Linehan, President
David Loew, President, MBA
Muzammil Mansuri, President, Ph.D
Klaus Pohle, Director
Diane Souza, Director
Bernard Charles, Director, Ph.D
Carole Piwnica, Director
Elias Zerhouni, President, Ph.D
Ameet Nathwani, President
Philippe Luscan, President
Roberto Pucci, President
DavidAlexandre Gros, President
Olivier Charmeil, President
Melanie Lee, Director, Ph.D
Igor Landau, Director
Patrick Kron, Director
Bonnie Bassler, Director
Thomas Suedhof, Director
Laurent Attal, Director
JeanRene Fourtou, Director
Gerard Kemmel, Director, MBA
SuetFern Lee, Director
Carsten Hellmann, President
David Meeker, President, Ph.D
Christian Mulliez, Director
Robert Castaigne, Director, Ph.D
Alan Main, President
Suet Lee, Director
Jerome Contamine, President
Uwe Bicker, Director, Ph.D

Stock Performance Indicators

Current Sentiment - SNYNF

Sanofi Investor Sentiment
Most of Macroaxis users are at this time bullish on Sanofi. What is your outlook on investing in Sanofi? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
OZL   
Purchased over 100 shares of
six days ago
Traded for 10.44
FBU   
Purchased over 300 shares of
six days ago
Traded for 6.24
JBH   
Purchased over 70 shares of
six days ago
Traded for 23.42
GNC   
Purchased over 200 shares of
six days ago
Traded for 8.1
SBM   
Purchased over 400 shares of
six days ago
Traded for 4.74
Also please take a look at World Market Map. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.